Trans-pulmonary Biomarkers in Pulmonary Hypertension
Active, not recruiting
- Conditions
- Pulmonary Hypertension
- Registration Number
- NCT01961232
- Lead Sponsor
- Vanderbilt University
- Brief Summary
The investigators are testing whether the addition of Pulmonary Hypertension-related biomarkers, measured across the pulmonary circulation, to the standard hemodynamic evaluation for Pulmonary Hypertension will lead to more informed choices of Pulmonary Hypertension therapy and improved patient outcomes.
- Detailed Description
Eligible participants with known or suspected Pulmonary Hypertension undergoing a clinically indicated right heart catheterization may be enrolled. Clinical data and blood samples will be analyzed.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Age ≥ 18 years old
- Undergoing RHC for PH evaluation
Exclusion Criteria
- Anemia defined as Hgb < 10 g/dL and HCT < 30
- Pregnancy at the time of RHC (as assessed by urine or serum pregnancy test on the day of the procedure)
- Left ventricular ejection fraction ≤ 40%
- Atrial fibrillation at the time of RHC (as defined by telemetry monitoring or EKG on the day of the procedure)
- IPF, CTEPH, COPD/OSA as the dominant etiology of PH
- Patient is currently taking PH medication or long-acting nitrates at the time of their RHC.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Differences in Pulmonary Hypertension biomarkers in patients evaluated for Pulmonary Hypertension At baseline
- Secondary Outcome Measures
Name Time Method Vasodilator-induced changes in Pulmonary Hypertension biomarkers At baseline Vasodilator-induced changes in Pulmonary Vascular Resistance (PVR) At baseline
Trial Locations
- Locations (1)
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States